Please try another search
For the three months ended 31 March 2022, TherapeuticsMD Inc revenues decreased 3% to $19.3M. Net loss increased 24% to $49M. Revenues reflect Prescription vitamins segment decrease of 39% to $875K, ANNOVERA segment decrease of 3% to $8.5M. Higher net loss reflects Amortization of deferred financing costs increase from $1.3M to $9M (expense), Other Income - Net decrease from $122K (income) to $0K.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 19.33 | 18.68 | 25.41 | 23 |
Gross Profit | 14.47 | 13.94 | 20.12 | 18.87 |
Operating Income | -34.61 | -35.39 | -39.92 | -35.18 |
Net Income | -49.02 | -42.96 | -47.42 | -42.65 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 133.38 | 169.47 | 209.63 | 210.6 |
Total Liabilities | 273.96 | 263.09 | 266.99 | 259.68 |
Total Equity | -140.58 | -93.62 | -57.36 | -49.07 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -29.53 | -142.69 | -103.14 | -64.91 |
Cash From Investing Activities | -0.21 | -2.22 | -0.71 | -0.53 |
Cash From Financing Activities | -5 | 129.55 | 128.2 | 96.38 |
Net Change in Cash | -34.74 | -15.36 | 24.36 | 30.94 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review